Osiris Therapeutics Inc. (NASDAQ: OSIR) announced today it has received
market authorization from Health Canada to market its stem cell therapy
Prochymal® (remestemcel-L), for the treatment of acute
graft-vs-host disease (GvHD) in children. The historic decision marks
the world's first regulatory approval of a manufactured stem cell
product and the first therapy approved for GvHD — a devastating
complication of bone marrow transplantation that kills up to 80 percent
of children affected, many within just weeks of diagnosis.
"I am very proud of the leadership role Canada has taken in advancing
stem cell therapy and particularly gratified that this historic decision
benefits children who would otherwise have little hope," said Andrew
Daly, M.D., Clinical Associate Professor, Department of Medicine and
Oncology at the University of Calgary, Canada and Principal Investigator
in the phase 3 clinical program for Prochymal. "As a result of Health
Canada's comprehensive review, physicians now have an off-the-shelf stem
cell therapy in their arsenal to fight GvHD. Much like the introduction
of antibiotics in the late 1920's, with stem cells we have now
officially taken the first step into this new paradigm of medicine."
Prochymal was authorized under Health Canada's Notice of Compliance with
conditions (NOC/c) pathway, which provides access to therapeutic
products that address unmet medical conditions and which have
demonstrated a favorable risk/benefit profile in clinical trials. Under
the NOC/c pathway, the sponsor must agree to carry out confirmatory
"Today is not only a great day for Osiris, but for everyone involved in
the responsible development of stem cell therapies," said C. Randal
Mills, Ph.D., President and Chief Executive Officer of Osiris. "Most
importantly, today is a great day for children and their families who
bravely face this horrific disease. While today marks the first approval
of a stem cell drug, now that the door has been opened, it will surely
not be the last."
Health Canada’s authorization was made following the recommendation of an independent expert advisory panel, commissioned to evaluate Prochymal's safety and efficacy. In Canada, Prochymal is now authorized for the management of acute GvHD in children who fail to respond to steroids. The approval was based on the results from clinical studies evaluating Prochymal in patients with severe refractory acute GvHD. Prochymal demonstrated a clinically meaningful response at 28 days post initiation of therapy in 61-64 percent of patients treated. Furthermore, treatment with Prochymal resulted in a statistically significant improvement in survival when compared to a historical control population of pediatric patients with refractory GvHD (p=0.028). The survival benefit was most pronounced in patients with the most severe forms of GvHD. As a condition of approval, the clinical benefit of Prochymal will be further evaluated in a case matched confirmatory trial and all patients receiving Prochymal will be encouraged to participate in a registry that will monitor the long-term effects of the therapy.